Tags
Cancer, FDA, Litigation & Trial, Max Kennerly, Medicaid, Medicare, Pfizer, Prescription Drugs, RICO, Schering–Plough
Send In The Lawyers: A Partial Fix For America’s Dystopian Prescription Drug Market, by Max Kennerly, Esq., Litigation & Trial Blog
It’s hard to read any news about prescription drugs these days without wondering if you’ve somehow fallen into a Philip K. Dick novel. Just look at some of these titles over the past week:
- ‘2 new studies show the FDA is rushing more drugs to market based on shoddy evidence’
- ‘The True Cost of an Expensive Medication’
- ‘U.S. drug company sues Canada for trying to lower cost of $700K-a-year drug’
- ‘Outrage could lead to lowering price of high-cost drugs’
All of these stories are about different drugs, but the common theme among all of the stories is, of course, money. The Mayo Clinical Proceedings recently found ‘In the United States, the average price of cancer drugs for about a year of therapy increased from $5000 to $10,000 before 2000 to more than $100,000 by 2012, while the average household income has decreased by about 8% in the past decade. Further, although 85% of cancer basic research is funded through taxpayers’ money, Americans with cancer pay 50% to 100% more for the same patented drug than patients in other countries.’ . . .
